CIFE strongly opposes the expansion of the TRIPS waiver. Intellectual property rights are essential for promoting innovation, investment, and economic growth. The TRIPS agreement already provides adequate flexibilities to ensure access to medicines in times of public health emergencies. We believe that an expansion of the TRIPS waiver would undermine the incentives for companies to invest in research and development, leading to a negative impact on future medical breakthroughs. Instead, we support a collaborative approach that balances the need for access to medicines with the importance of maintaining a robust and sustainable innovation ecosystem.